Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains

Talebi Bezmin Abadi, A.; Petrosillo, N.; Kavoor, A.R.

doi:10.1016/j.vacune.2020.08.001

array:22 ["pii" => "S2445146021000236" "issn" => "24451460" "doi" => "10.1016/j.vacune.2020.08.001" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "159" "copyrightAnyo" => "2021" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:129-30" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:18 [ "pii" => "S1576988720300406" "issn" => "15769887" "doi" => "10.1016/j.vacun.2020.08.001" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "159" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:129-30" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "129" "paginaFinal" => "130" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Circulación simultánea de virus de la gripe estacional y cepas SARS CoV-2" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Talebi Bezmin Abadi, N. Petrosillo, A.R. Kavoor" "autores" => array:3 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Talebi Bezmin Abadi" ] 1 => array:2 [ "nombre" => "N." "apellidos" => "Petrosillo" ] 2 => array:2 [ "nombre" => "A.R." "apellidos" => "Kavoor" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2445146021000236" "doi" => "10.1016/j.vacune.2020.08.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000236?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988720300406?idApp=UINPBA00004N" "url" => "/15769887/0000002200000002/v1_202106120702/S1576988720300406/v1_202106120702/en/main.assets" ] ] "itemAnterior" => array:19 [ "pii" => "S2445146021000261" "issn" => "24451460" "doi" => "10.1016/j.vacune.2020.12.001" "estado" => "S300" "fechaPublicacion" => "2021-05-01" "aid" => "177" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Vacunas. 2021;22:127-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "The future role of pharmacists and pharmacovigilance after the advent of the COVID-19 pandemic" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "127" "paginaFinal" => "128" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Rol de farmacéuticos y farmacovigilancia tras la aparición de la pandemia de COVID-19" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. La Gatta, F. Ghidinelli" "autores" => array:2 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "La Gatta" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Ghidinelli" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1576988721000066" "doi" => "10.1016/j.vacun.2020.12.003" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1576988721000066?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000261?idApp=UINPBA00004N" "url" => "/24451460/0000002200000002/v1_202106241110/S2445146021000261/v1_202106241110/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "Letter to the Editor" "titulo" => "Simultaneous occurrence of seasonal influenza virus and SARS CoV-2 strains" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "129" "paginaFinal" => "130" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "A. Talebi Bezmin Abadi, N. Petrosillo, A.R. Kavoor" "autores" => array:3 [ 0 => array:4 [ "nombre" => "A." "apellidos" => "Talebi Bezmin Abadi" "email" => array:1 [ 0 => "Amin.talebi@modares.ac.ir" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "N." "apellidos" => "Petrosillo" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "A.R." "apellidos" => "Kavoor" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Department of Bacteriology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "National Institute for Infectious Diseases “L. Spallanzani”, IRCCS, Rome, Italy" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Queensland Health, Australia; University of Queensland, Australia" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Circulación simultánea de virus de la gripe estacional y cepas SARS CoV-2" ] ] "textoCompleto" => "A baffling pathogen called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), initially termed as 2019-nCoV, is the lone cause of the current pandemic, spanning across six continents.<a class="elsevierStyleCrossRef" href="#bib0030">1</a> The causative agent of coronavirus disease 2019 (COVID-19) was isolated from a surge of subjects that were referred to hospitals with flu-like illness and its rapid spread is having a major impact on cultural, economic and social aspects. SARS-CoV-2 that originated from Wuhan, Hubei province at China's mainland is admissibly considered a serious threat to human life due to its high contagiousness, poorly known pathogenesis, and potential to result in severe outcomes such as ARDS and multi-organ failure within a short period of time following disease onset.<a class="elsevierStyleCrossRef" href="#bib0035">2</a> Foreseeably, there are three putative outcomes of the current SARS-COV-2 pandemic. First and most conspicuous approach is to develop a preventive vaccine that can heighten herd immunity against SARS-CoV-2 and avert new COVID-19 cases. There are numerous research groups relentlessly working to provide such a biological product, but unfortunately, it is not practical to envisage this product within a period shorter than 10–15 months from now (April 2020). Development and approval of the vaccine against SARS-CoV-2 for mass administration across the world at this stage seems like a farfetched idea as well. Second approach could be the discovery and introduction of an effective anti-viral agent which is the most challenging ordeal during an uncontrolled outbreak.<a class="elsevierStyleCrossRef" href="#bib0040">3</a> Notably, there are some candidates in the pipeline yet to be approved by international organizations like FDA, while the definite effectiveness of these drugs can only become apparent to scientists over time. The third possible outcome is flattening the epidemic curve by effective lockdown, isolation of COVID-19 positive subjects by PCR, quarantine of contacts, active screening and case finding, social distancing, hand hygiene, use of masks, and so on. Fourth predictable scenario is to wait for the spontaneous cessation of the pandemic, which is the most inert approach at this point. It may mean that we reluctantly accept this unwelcome guest in our clinics and even deal with it annually, whether it's mild or severe. The historic concepts of herd immunity make this epidemiologic measure a plausible option, although there is no consensus on generalizing it to all populations with scarce knowledge about case fatality rate of SARS-CoV-2. Apart from the above four mentioned scenarios, we hypothesize a possibility of an ongoing pandemic caused by two super-spreading agents, the SARS-CoV-2 and seasonal flu. The clinical dilemma involved here is that more than 80% of coronavirus symptoms tend to be mild which makes it difficult to differentiate it from flu. The coincidental occurrence of such viral infections may be uncountable if it appears at the time of a flu epidemic.<a class="elsevierStyleCrossRef" href="#bib0040">3</a>Furthermore, another predictable situation is a new mutated strain of SARS-CoV which could be named SARS-CoV-3 causing COVID-20 or COVID-21 in the upcoming years, and in contemporaneous occurrence with seasonal influenza virus. We speculate that the threat of such a coincidence could be far greater for public health. Consequently, there is a need to remain vigilant of an overlap between influenza virus and SARS-CoV-2 during expected periods of seasonal flu. Seasonal influenza is transmitted via droplet which is also the predominant mode of transmission for SARS CoV-2. Relatively similar symptoms and transmission routes, (droplet and close contact between infector and infected) are supporting evidence and a cause for concern in the coming months of 2020 and 2021. Although mortality rate for COVID-19 (around 3%) is higher than flu (less than 0.1%), the more severe consequences of such co-infections may result in detrimental clinical outcomes.<a class="elsevierStyleCrossRefs" href="#bib0045">4,5</a> Although a global action was suggested to battle COVID-19 pandemic, we need more rigorous measures to withstand upcoming outbreaks which could be a conglomeration of infections by both viruses. In conclusion, application of compulsory influenza and pneumococcal vaccines especially for population older than 65 years are highly recommended.Authorship and manuscript preparationAmin Talebi and Nicola Petrosillo contributed to the conception of the work, performed literature searches, drafted the initial text, and approved the final version for publication. Anjana Rao Kavoor and Amin Talebi revised the manuscript for important intellectual content, contributed to the ideas and discussions presented in the letter, edited and drafted the manuscript, and all approved the final version of the manuscript for publication. The views presented in this letter are of the authors and do not represent the views of their employers.Ethical approvalNot applicable.Financial supportNo funding was received for writing or publishing this manuscript.Conflict of interestThe authors declare that they have no conflict of interest." "textoCompletoSecciones" => array:1 [ "secciones" => array:5 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Authorship and manuscript preparation" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Ethical approval" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Financial support" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Conflict of interest" ] 4 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "The following are the supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia>" "etiqueta" => "Appendix A" "titulo" => "Supplementary data" "identificador" => "sec0030" ] ] ] ] "multimedia" => array:1 [ 0 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 254020 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib0030" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "World Health Organization (2020) Coronavirus disease 2019 (COVID19): situation report—51. WHO, Geneva. <a target="_blank" href="https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep51-covid-19.pdf?sfvrsn=1ba62e57_10">https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep51-covid-19.pdf?sfvrsn=1ba62e57_10</a>." ] ] ] 1 => array:3 [ "identificador" => "bib0035" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19: what is next for public health?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "D.L. Heymann" 1 => "N. Shindo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(20)30374-3" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2020" "volumen" => "395" "paginaInicial" => "542" "paginaFinal" => "545" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32061313" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0040" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Ko W-C, Rolain J-M, Lee N-Y, Chen P-L, Huang C-T, Lee P-I, et al. Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents; 2020. <a target="_blank" href="doi:10.1016/j.ijantimicag.2020.105933">doi:10.1016/j.ijantimicag.2020.105933</a>." ] ] ] 3 => array:3 [ "identificador" => "bib0045" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "COVID-19 SARS and MERS: are they closely related?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "N. Petrosillo" 1 => "G. Viceconte" 2 => "O. Ergonul" 3 => "G. Ippolito" 4 => "E. Petersen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.cmi.2020.03.026" "Revista" => array:6 [ "tituloSerie" => "Clin Microbiol Infect" "fecha" => "2020" "volumen" => "26" "paginaInicial" => "729" "paginaFinal" => "734" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32234451" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0050" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Impact of influenza vaccination on seasonal mortality in the US elderly population" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "L. Simonsen" 1 => "T.A. Reichert" 2 => "C. Viboud" 3 => "W.C. Blackwelder" 4 => "R.J. Taylor" 5 => "M.A. Miller" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archinte.165.3.265" "Revista" => array:6 [ "tituloSerie" => "Arch Intern Med" "fecha" => "2005" "volumen" => "165" "paginaInicial" => "265" "paginaFinal" => "272" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/15710788" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/24451460/0000002200000002/v1_202106241110/S2445146021000236/v1_202106241110/en/main.assets" "Apartado" => array:4 [ "identificador" => "91117" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/24451460/0000002200000002/v1_202106241110/S2445146021000236/v1_202106241110/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2445146021000236?idApp=UINPBA00004N"]

ISSN: 2445-1460

Official journal of the Asociación Española de Vacunología (AEV) Vacunas is a peer-reviewed journal supported by an advisory board of experts in the field of vaccinology. The aim of the journal is to contribute to the dissemination of the scientific advances made in the area of basic and applied research in the field of vaccine-preventable diseases in humans. It places special emphasis on aspects associated with planning and evaluation (epidemiology of vaccine-preventable diseases, development of vaccination programs, evaluation of the efficacy, effectiveness and efficiency of vaccinations). Vacunas publishes, in Spanish and in English, Editorials, Original Articles, Special Articles, Reviews, Strategies and Vaccination Programs. There are also sections on Literature Reviews, News and on Congresses associated with vaccinations. The peer review process is done anonymously by reviewers with expertise in the area of knowledge of each manuscript as well as experts in methodology or statistics, as determined by the Editorial board, which works towards maintaining an efficient editorial process in order for the manuscripts to be published as soon as possible.

See more Open Access Option

Indexed in:

Scopus, EMBASE/Excerpta Médica e IBECS

Subscribe:

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.9

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.423

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.421

View more metrics

Journal Information

Previous article | Next article

Vol. 22. Issue 2.